The FDA granted priority review to Daiichi Sankyo and Merck’s ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, for advanced extensive-stage small-cell lung cancer. The accelerated timeline underscores regulators’ focus on new ADCs targeting solid-tumor surface markers, with ifinatamab deruxtecan now moving through the BLA review at heightened speed.